110 related articles for article (PubMed ID: 17504980)
1. Standardizing slide-based assays in breast cancer: hormone receptors, HER2, and sentinel lymph nodes.
Ross JS; Symmans WF; Pusztai L; Hortobagyi GN
Clin Cancer Res; 2007 May; 13(10):2831-5. PubMed ID: 17504980
[TBL] [Abstract][Full Text] [Related]
2. Randomized phase 3 trial of fluorouracil, epirubicin, and cyclophosphamide alone or followed by Paclitaxel for early breast cancer.
Martín M; Rodríguez-Lescure A; Ruiz A; Alba E; Calvo L; Ruiz-Borrego M; Munárriz B; Rodríguez CA; Crespo C; de Alava E; López García-Asenjo JA; Guitián MD; Almenar S; González-Palacios JF; Vera F; Palacios J; Ramos M; Gracia Marco JM; Lluch A; Alvarez I; Seguí MA; Mayordomo JI; Antón A; Baena JM; Plazaola A; Modolell A; Pelegrí A; Mel JR; Aranda E; Adrover E; Alvarez JV; García Puche JL; Sánchez-Rovira P; Gonzalez S; López-Vega JM;
J Natl Cancer Inst; 2008 Jun; 100(11):805-14. PubMed ID: 18505968
[TBL] [Abstract][Full Text] [Related]
3. Triple-negative breast cancer types exhibit a distinct poor clinical characteristic in lymph node-negative Chinese patients.
Liu ZB; Liu GY; Yang WT; Di GH; Lu JS; Shen KW; Shen ZZ; Shao ZM; Wu J
Oncol Rep; 2008 Oct; 20(4):987-94. PubMed ID: 18813844
[TBL] [Abstract][Full Text] [Related]
4. Prognostic utility of fluorescence in situ hybridization for determining HER2 gene amplification in breast cancer.
Kammori M; Kurabayashi R; Kashio M; Sakamoto A; Yoshimoto M; Amano S; Kaminishi M; Yamada T; Takubo K
Oncol Rep; 2008 Mar; 19(3):651-6. PubMed ID: 18288397
[TBL] [Abstract][Full Text] [Related]
5. [Immunochemistry evaluation of HER2 status in infiltration breast cancer: technical protocol and interpretation guidelines].
Penault-Llorca F; Balaton A; Sabourin JC; Le Doussal V;
Ann Pathol; 2002 Apr; 22(2):150-7. PubMed ID: 12124503
[TBL] [Abstract][Full Text] [Related]
6. Detection of circulating tumor cells in early-stage breast cancer metastasis to axillary lymph nodes.
Nakagawa T; Martinez SR; Goto Y; Koyanagi K; Kitago M; Shingai T; Elashoff DA; Ye X; Singer FR; Giuliano AE; Hoon DS
Clin Cancer Res; 2007 Jul; 13(14):4105-10. PubMed ID: 17634536
[TBL] [Abstract][Full Text] [Related]
7. Validation of the Tenon breast cancer score for predicting non-sentinel lymph node status in breast cancer patients with sentinel lymph node metastasis: a prospective multicenter study.
Coutant C; Rouzier R; Fondrinier E; Marchal F; Guillemin F; Seince N; Rodrigues A; Darai E; Uzan S; Barranger E
Breast Cancer Res Treat; 2009 Feb; 113(3):537-43. PubMed ID: 18340527
[TBL] [Abstract][Full Text] [Related]
8. Commentary: hormone receptor testing in breast cancer: a distress signal from Canada.
Allred DC
Oncologist; 2008 Nov; 13(11):1134-6. PubMed ID: 18987048
[No Abstract] [Full Text] [Related]
9. Human epidermal growth factor receptor 2 status correlates with lymph node involvement in patients with estrogen receptor (ER) negative, but with grade in those with ER-positive early-stage breast cancer suitable for cytotoxic chemotherapy.
Bartlett JM; Ellis IO; Dowsett M; Mallon EA; Cameron DA; Johnston S; Hall E; A'Hern R; Peckitt C; Bliss JM; Johnson L; Barrett-Lee P; Ellis P
J Clin Oncol; 2007 Oct; 25(28):4423-30. PubMed ID: 17906205
[TBL] [Abstract][Full Text] [Related]
10. Sentinel lymph node biopsy after neoadjuvant chemotherapy is accurate in breast cancer patients with a clinically negative axillary nodal status at presentation.
Gimbergues P; Abrial C; Durando X; Le Bouedec G; Cachin F; Penault-Llorca F; Mouret-Reynier MA; Kwiatkowski F; Maublant J; Tchirkov A; Dauplat J
Ann Surg Oncol; 2008 May; 15(5):1316-21. PubMed ID: 18311507
[TBL] [Abstract][Full Text] [Related]
11. HER2 status in hormone receptor positive premenopausal primary breast cancer adds prognostic, but not tamoxifen treatment predictive, information.
Rydén L; Landberg G; Stål O; Nordenskjöld B; Fernö M; Bendahl PO
Breast Cancer Res Treat; 2008 May; 109(2):351-7. PubMed ID: 17636399
[TBL] [Abstract][Full Text] [Related]
12. Touch imprint cytology with cytokeratin immunostaining versus Papanicolau staining for intraoperative evaluation of sentinel lymph node metastasis in clinically node-negative breast cancer.
Fujishima M; Watatani M; Inui H; Hashimoto Y; Yamamoto N; Hojo T; Hirai K; Yamato M; Shiozaki H
Eur J Surg Oncol; 2009 Apr; 35(4):398-402. PubMed ID: 18434073
[TBL] [Abstract][Full Text] [Related]
13. Accuracy of fine-needle aspiration cytology of axillary lymph nodes in breast cancer patients: a study of 115 cases with cytologic-histologic correlation.
Alkuwari E; Auger M
Cancer; 2008 Apr; 114(2):89-93. PubMed ID: 18286535
[TBL] [Abstract][Full Text] [Related]
14. Axillary lymph node status of operable breast cancers by combined steroid receptor and HER-2 status: triple positive tumours are more likely lymph node positive.
Van Calster B; Vanden Bempt I; Drijkoningen M; Pochet N; Cheng J; Van Huffel S; Hendrickx W; Decock J; Huang HJ; Leunen K; Amant F; Berteloot P; Paridaens R; Wildiers H; Van Limbergen E; Weltens C; Timmerman D; Van Gorp T; Smeets A; Van den Bogaert W; Vergote I; Christiaens MR; Neven P
Breast Cancer Res Treat; 2009 Jan; 113(1):181-7. PubMed ID: 18264760
[TBL] [Abstract][Full Text] [Related]
15. Improved breast cancer biomarker detection through a simple, high frequency, low cost external proficiency testing program.
Hung T; Wolber R; Garratt J; Kalloger S; Gilks CB
Pathology; 2010 Dec; 42(7):637-42. PubMed ID: 21080872
[TBL] [Abstract][Full Text] [Related]
16. A decision tool for predicting sentinel node accuracy from breast tumor size and grade.
Coombs N; Chen W; Taylor R; Boyages J
Breast J; 2007; 13(6):593-8. PubMed ID: 17983402
[TBL] [Abstract][Full Text] [Related]
17. Lower level of MAPK expression is associated with anthracycline resistance and decreased survival in patients with hormone receptor negative breast cancer.
Derin D; Eralp Y; Ozluk Y; Yavuz E; Guney N; Saip P; Igci A; Ozmen V; Kücücük S; Aslay I; Aydiner A; Topuz E
Cancer Invest; 2008 Aug; 26(7):671-9. PubMed ID: 18608215
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of new monoclonal antibodies in detection of estrogen receptor, progesterone receptor, and Her2 protein expression in breast carcinoma cell block sections using conventional microscopy and quantitative image analysis.
Hanley KZ; Siddiqui MT; Lawson D; Cohen C; Nassar A
Diagn Cytopathol; 2009 Apr; 37(4):251-7. PubMed ID: 19217031
[TBL] [Abstract][Full Text] [Related]
19. Immunohistochemical markers as predictive tools for breast cancer.
Walker RA
J Clin Pathol; 2008 Jun; 61(6):689-96. PubMed ID: 18037665
[TBL] [Abstract][Full Text] [Related]
20. Comparison of triple-negative and estrogen receptor-positive/progesterone receptor-positive/HER2-negative breast carcinoma using quantitative fluorine-18 fluorodeoxyglucose/positron emission tomography imaging parameters: a potentially useful method for disease characterization.
Basu S; Chen W; Tchou J; Mavi A; Cermik T; Czerniecki B; Schnall M; Alavi A
Cancer; 2008 Mar; 112(5):995-1000. PubMed ID: 18098228
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
